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ABSTRACT  42 
Background 43 
Although several studies of risk factors for prevalence of meningococcal carriage in the 44 
African meningitis belt have been reported, few have examined risk factors for acquisition. 45 
We investigated a range of potential risk factors for acquisition in seven countries of the 46 
meningitis belt.  47 
Methods 48 
Households were followed up every two weeks for two months, then monthly for a further 49 
four months. Pharyngeal swabs were collected from all available household members at each 50 
visit and questionnaires completed. Risks of acquisition over the whole study period and for 51 
each visit were analysed by a series of logistic regressions.  52 
Results 53 
Over the course of the study, acquisition was higher in: (i) 5-14 year olds, as compared with 54 
those 30 years or older (OR 3.6, 95%CI 1.4-9.9); (ii) smokers (OR 3.6, 95%CI 0.98-13); and (iii) 55 
those exposed to wood smoke at home (OR 2.6 95%CI 1.3-5.6). The risk of acquisition from 56 
one visit to the next was higher in those reporting a sore throat during the dry season (OR 57 
3.7, 95%CI 2.0-6.7) and lower in those reporting antibiotic use (OR 0.17, 95%CI 0.03-0.56).  58 
Conclusions 59 
Acquisition of meningococcal carriage peaked in school age children. Recent symptoms of 60 
sore throat during the dry season, but not during the rainy season, were associated with a 61 
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higher risk of acquisition. Upper respiratory tract infections may be an important driver of 62 
epidemics in the meningitis belt. 63 
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BACKGROUND 64 
Epidemics of meningococcal meningitis occur periodically in the African Meningitis Belt, an 65 
area of sub-Saharan Africa stretching from Senegal in the west to Ethiopia in the east.[1] 66 
These epidemics are highly seasonal, with the majority of cases occurring during the dry 67 
season, predominantly in the first five months of the year.[2] Given that asymptomatic 68 
pharyngeal carriage of meningococci is relatively frequent (ranging from 3-30% of the 69 
population)[3] and because meningococcal acquisition only occasionally leads to invasive 70 
disease, one explanation for this striking seasonality is an increased risk of invasive disease in 71 
the dry season, due to mucosal damage from environmental factors such as low absolute 72 
humidity and dust.[1,4,5] Another hypothesis suggested by mathematical modelling is that 73 
higher rates of meningococcal transmission during the dry season, combined with population 74 
immunity, may be sufficient to explain epidemic patterns.[6] Although a review of carriage in 75 
the meningitis belt published in 2007 found no evidence to support a seasonal effect on 76 
carriage,[3] more recent studies have found a higher prevalence of carriage in the dry 77 
season.[7,8]  78 
Studies of carriage prevalence and acquisition will, therefore, lead to a better understanding 79 
of the epidemiology of meningococcal meningitis in the African meningitis belt. The African 80 
Meningococcal Carriage Consortium (MenAfriCar) undertook 20 cross-sectional carriage 81 
surveys in seven African meningitis belt countries from July 2010 to July 2012, involving the 82 
collection of over 48,000 pharyngeal swabs. These studies found a higher frequency of 83 
carriage in children aged 5-14 years, in the dry season and in rural populations.[7] During 84 
these surveys, households with at least one pharyngeal carrier of N. meningitidis were 85 
recruited for longitudinal studies.[9] 86 
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Previous longitudinal studies in the meningitis belt have been undertaken mainly at the 87 
population level [10–12] and few have investigated the transmission and acquisition of 88 
carriage at an individual level.[13,14] The aim of this MenAfriCar study was to investigate a 89 
comprehensive set of potential risk factors for the acquisition of carriage of N. meningitidis 90 
across the African meningitis belt.  91 
METHODS  92 
Household surveys 93 
Households included in this study were recruited during the course of cross-sectional surveys 94 
conducted in seven countries in the African meningitis belt (Chad, Ethiopia, Ghana, Mali, 95 
Niger, Nigeria and Senegal) in 2010, 2011, and 2012. Details of the survey methods employed 96 
have been published previously.[7] Longitudinal surveys were triggered by the identification 97 
of a putative carrier during a cross-sectional survey (Visit 0). This initial identification of 98 
carriers relied on conventional microbiology and was later confirmed via molecular methods 99 
at the University of Oxford. In some cases, molecular methods did not confirm the presence 100 
of meningococci, so 51 of 184 households recruited to the study did not have an index carrier. 101 
Within four weeks of the identification of a carrier, all members of the putative carrier’s 102 
household were invited to take part in further studies (Visit 1). The head of the household 103 
was asked about characteristics of the household, including numbers of rooms and bedrooms, 104 
sleeping arrangements, location of kitchen and cooking fuel, house construction, drinking 105 
water, sanitation, and household assets such as vehicle ownership, livestock, and electrical 106 
goods.  107 
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A pharyngeal swab sample  was obtained from all members of a household who gave their 108 
consent and a questionnaire completed which included questions on: smoking; social 109 
activities; symptoms of recent respiratory tract infection; socio-economic status and 110 
educational level; school attendance; travel history; recent medication including antibiotics; 111 
meningitis vaccination; and ethnic group. Carrier households were followed up two-weekly 112 
for two months (Visits 2-5) and monthly for a further four months (Visits 5-9). At each follow 113 
up visit, each household member was asked for a pharyngeal swab sample and to answer a 114 
short follow-up questionnaire on factors that might have changed since the previous visit, 115 
such as symptoms of a respiratory tract infection. 116 
Laboratory methods 117 
Pharyngeal swab samples, taken from the posterior pharynx and tonsillar fossa via the mouth, 118 
were plated directly onto Modified Thayer Martin agar plates in the field, taken to the 119 
laboratory within six hours of collection, and processed as previously described.[9] A sample 120 
of boiled suspensions of Gram negative oxidase positive bacteria was sent to the University 121 
of Oxford for molecular analysis. Amplification and sequencing of the rplF gene was used to 122 
confirm the presence of, and differentiate between, Neisseria species. Confirmed N. 123 
meningitidis were further characterised by genogroup (including capsule null) and porA 124 
genosubtype. 125 
Data management  126 
Data were managed using the Teleform system version 10.4.1 (Autonomy, Cambridge UK) 127 
with a separate database module linking the main study database with genetic laboratory 128 
results from the Oxford PubMLST.org/neisseria database (https://pubmlst.org/neisseria). 129 
Data from the longitudinal questionnaires were merged using a common person ID, or census 130 
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number, person matching was checked, any duplicate entries were removed, and aberrant 131 
values excluded.  132 
Statistical analysis 133 
The genogroup-specific acquisition rates and 95% confidence intervals were calculated as 134 
Poisson rates, counting the number of acquisitions occurring in non-index carriers and the 135 
time at risk as the days between the first carriage-negative swab and the first positive 136 
swab. A series of fixed-effects logistic regressions were used to identify significant risk 137 
factors for acquisition. In the first round of regressions, individual risk factors were included 138 
in a multivariable logistic regression with the a priori variables sex, age group, and country. 139 
In the second round, risk factors with p<0.1 in round 1 were added to a single model with a 140 
priori variables. In the third round, risk factors with p<0.05 in round 2 were retained in the 141 
multivariable model. In the fourth round, all factors dropped in round 3 were added back in 142 
to the model one by one and all variables with p<0.05 were retained, giving the final 143 
models. The study-long and visit-by-visit models were then run with household ID and both 144 
household and individual ID as random effects, respectively, to account for clustering, and 145 
factors that were no longer significant (p>=0.05) were dropped.  146 
Acquisition was assessed over the full study period (study-long) and visit-by-visit. 147 
Individuals were defined as positive for study-long acquisition if they had a negative swab 148 
(no meningococci isolated) at visits 0 or 1 and a positive swab (any meningococci isolated) 149 
at any following visit.  Individuals were defined as negative for study-long acquisition if they 150 
had a negative swab at visits 0 or 1 and no positive swab at any subsequent visit.  151 
Individuals with three or more missed visits in total were excluded, as the possibility of 152 
acquisition during this missed period could not be ruled out, and individuals carrying at 153 
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visits 0 or 1 were also excluded. 154 
Individuals were defined as positive for visit-by-visit acquisition on a given visit if the 155 
individual had a positive swab at the current visit and a negative swab at the previous visit 156 
or carried a different strain at the previous visit and the strain was not previously carried 157 
during the study. Strains were assessed by genogroup and porA variable regions 1 and 2. 158 
Individuals were defined as negative for visit-by-visit acquisition on a given visit if the 159 
individual had a negative swab at the previous visit and a negative swab at the current visit. 160 
Individuals carrying an identical strain to that obtained at the previous visit and individuals 161 
who cleared carriage were excluded from the analysis. Tables S1 and S2 provide the 162 
classification of cases for study-long and visit-by-visit acquisition. 163 
We defined the dry season as January to May and the rainy season as June to December. 164 
Because we found a significant association between sore throat and season and because 165 
previous studies have demonstrated an interaction between meningococcal carriage, upper 166 
respiratory tract infection, and season, we also tested for interaction between sore throat 167 
and season in our final model and found that the model with an interaction term fitted 168 
better than the model with no interaction (Table S4). 169 
Ethics 170 
The study was approved by the ethics committee of the London School of Hygiene and 171 
Tropical Medicine and by the relevant ethical authorities in each African centre.[9] The head 172 
of the household or another responsible adult gave verbal informed consent for the 173 
household to be included in the study. Each individual recruited within that household gave 174 
written informed consent; for children under the age of 18 years a parent or guardian gave 175 
written consent and children aged over 12 years were additionally asked to give written 176 
assent. 177 
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RESULTS 178 
Acquisition over course of the study  179 
Overall, 169/861 (20%) of non-index carriers became pharyngeal carriers of a 180 
meningococcus at least once over the course of the study. A higher proportion of 5- to 14-181 
year-olds acquired carriage than other age groups, and a higher proportion of participants 182 
acquired carriage in Senegal, Niger, Ghana, and Ethiopia relative to Chad and Mali (Table 183 
1). A wide variation in acquisition rates was observed between countries. Genogroup W 184 
and capsule-null (cnl) meningococci accounted for the majority (83%) of acquisitions. The 185 
acquisition rates of genogroup W meningococci was 2.0% per month (95%CI 1.6-2.4) 186 
double that of cnl meningococci at 1.0% per month (95%CI 0.74-1.4). Genogroups A, C, Y, 187 
and other genogroup (i.e. other than A, B, C, W, X, Y or cnl) acquisitions were uncommon, 188 
and no genogroup B or X acquisitions were detected. 189 
In the final multivariable model, the highest odds of acquisition were among 5- to 14- year 190 
olds, with odds in all age groups under 30 years of age being significantly higher than the 191 
reference group of individuals 30 years and older (Table 1). Active smokers had higher odds 192 
of acquiring carriage than non-smokers living in households with no smokers,  with a lower 193 
confidence bound just below 1 (OR 3.57 95%CI 0.98-12.99). Non-smokers living in 194 
households with smokers also had elevated odds of acquisition but the difference was not 195 
statistically significant. Wood was the ubiquitous cooking fuel, with 96% of participants 196 
using this as cooking fuel; 56% of participants had additional wood smoke exposure. 197 
Participants with household exposure to wood smoke (independent of using wood as 198 
cooking fuel) had higher odds of acquiring carriage than those without (OR 2.60 95%CI 199 
1.26-5.59). Although this trend was not significant in the regression analysis, higher 200 
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acquisition rates were observed in households with an indoor kitchen and in households 201 
which used wood as the primary cooking fuel than in those who did not. 202 
Visit-specific Acquisition Analysis 203 
Participants who said they had had a sore throat since the previous visit during the dry season 204 
were significantly more likely (OR 3.67 95%CI 1.95-6.65) to have acquired carriage in that time 205 
period than those who did not have a sore throat in the rainy season (Table 2). Those who 206 
reported taking antibiotics since the previous visit were significantly less likely (OR 0.169 207 
95%CI 0.0271-0.564) to have acquired carriage.  208 
 209 
DISCUSSION 210 
This longitudinal study found a higher risk of acquisition amongst individuals who reported a 211 
sore throat since the previous visit, but only during the dry season. An association between 212 
an upper respiratory tract infection  and meningococcal carriage has been reported 213 
previously.[14] A sore throat could be due to an initial inflammation of the pharynx from 214 
meningococcal colonisation or could be caused by a concurrent unrelated infection that 215 
predisposes an individual to acquisition.[15] If the latter is true, upper respiratory tract 216 
infections in combination with dust and low humidity may be an important driver for the 217 
high risk of meningitis epidemics in the dry season.  This hypothesis is supported by a recent 218 
study indicating an association between upper respiratory tract infection (defined as otitis, 219 
severe sore throat and rhinopharyngitis) and meningitis outbreaks in Burkina Faso.[16] Such 220 
upper respiratory tract infections could plausibly increase both the risk of acquisition and 221 
the risk of invasion after acquisition.  222 
 223 
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The 5-14 year-old age group had the highest acquisition rate.  The highest prevalence of 224 
carriage in cross-sectional MenAfriCar studies and in Burkina Faso in 2009 was similarly 225 
highest in 5-14 year olds.[7,17] An overall acquisition rate of 2.4% (95% CI 1.6 to 4.0%) per 226 
month was estimated from a longitudinal household study using a hidden Markov model.[9] 227 
There were no significant differences reported by age group, but data were subdivided by 228 
control and index households and there was no adjustment for other risk factors. 229 
Additional factors linked to acquisition of meningococci over the course of this study were 230 
smoking tobacco and exposure to wood smoke.  Smoking, passive exposure to smoke and to 231 
smokers has been shown to convey a high risk of carriage and invasive disease in industrialised 232 
countries.[18–21] Exposure to cigarette smoke has also been linked to the risk of carriage in 233 
the meningitis belt.[7,14] The higher risk of acquisition from smoke exposure in this study 234 
suggests a direct risk from smoke itself, potentially from interference with mucosal immunity, 235 
as exposure to wood smoke was an independent risk factor. Exposure to smoke from wood 236 
fires has also been shown as a risk factor for meningococcal meningitis in northern Ghana.[22] 237 
Although use of wood as primary cooking fuel was not found to be a significant risk factor, 238 
this could be explained by the fact that nearly all study participants relied on wood as primary 239 
fuel or that some households used outdoor kitchens, thus moderating the degree of 240 
exposure. 241 
Strengths of this study are the multi-centre design across seven countries of the meningitis 242 
belt conducted at the same time, including a mix of urban and rural populations with a broad 243 
age range, the use of  standardised field and laboratory protocols and a large sample size. 244 
Measuring acquisition rather than carriage ensures that the risk factors identified in this study 245 
are not biased by factors associated with longer carriage duration. A comprehensive range of 246 
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risk factors was included, so that important confounding factors are unlikely to have been 247 
missed; however, the sampling of carriers and non-carriers was not random and we would 248 
expect some misclassification of carriage status from the known low sensitivity of pharyngeal 249 
swabbing.  250 
Both the acquisition of meningococci found in this longitudinal study and prevalence of 251 
carriage in the MenAfriCar cross-sectional studies varied considerably by country. Although 252 
laboratory methods were standardised across centres, differences in laboratory techniques 253 
could still have contributed to some of the differences observed. As most meningococcal 254 
acquisitions were either genogroup W or capsule-null and outside epidemics, it cannot be 255 
assumed that risk factors for acquisition of other genogroups or during epidemics would be 256 
the same as that found in this study.[23]  257 
It was surprising that some risk factors such as household crowding that have long been 258 
known to raise the risk of carriage and disease [7,13,24,25] were not associated in this study 259 
with acquisition. Crowding was measured here by numbers sharing a bedroom or bedmat, 260 
and by numbers of people per room in the household.  It is possible that crowded living 261 
conditions are so prevalent across the meningitis belt countries that any effect of crowding 262 
on acquisition is not detectable. A study in rural Gambia did not find any differences in crowding 263 
between compounds with and without cases of meningococcal meningitis during an 264 
epidemic.[26] 265 
Reported vaccination was clustered in particular time periods and countries corresponding to 266 
the introduction of group A conjugate vaccine. Vaccination was not found to be protective 267 
against carriage acquisition. However, we would not expect a group A conjugate vaccine to 268 
have a significant impact on carriage in this study as very few group A carriers were detected. 269 
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We were not able to draw any conclusions regarding the relationship between carriage 270 
acquisition and disease incidence because none of the study sites reported an outbreak of 271 
meningitis during the follow-up period.  272 
This study involved multiple countries and examined an exhaustive set of household and 273 
individual risk factors for meningococcal acquisition. The importance of identifying these 274 
risk factors is that acquisition is a necessary pre-requisite for invasive disease. Acquisition 275 
studies also play a potential role in vaccine evaluation. Of particular interest for countries of 276 
the African meningitis belt is the finding that symptoms of upper respiratory tract infection 277 
are linked to risk of acquisition, but only in the dry season. The evidence is mounting that 278 
such infections are an important factor behind the risk of epidemics in the meningitis belt.  279 
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Table 1. Risk factors for N. meningitidis acquisition over the full study period: single risk factor 362 
analysis and multi-variable model. Adjustment was made in both single and multi-variable analysis 363 
for age, country, and sex. 364 
Factor 
Single risk factor analysis Multi-variable model 
Total 
Positive 
(%) OR 95% CI Total 
Positive 
(%) OR 95% CI 
Age         
30 plus     205 11.7 1  
Under 5     91 28.6 3.12 (1.27,8.05) 
5-14     108 23.1 3.62 (1.42,9.93) 
15-29     161 21.1 2.38 (1.22,4.76) 
Country         
Chad     54 5.6 1  
Ethiopia     64 26.6 7.65 (1.81,44.4) 
Ghana     74 23 6.77 (1.52,40.1) 
Mali     157 5.7 0.532 (0.110,3.22) 
Niger     206 28.6 10.0 (2.53,57.3) 
Senegal     10 40 13.3 (1.23,159) 
Sex         
Female     326 17.5 1  
Male     239 21.8 1.00 (0.585,1.71) 
Exposure to wood smoke in 
house (apart from use in 
cooking)* 
        
No 372 20.2 1  261 19.2 1  
Yes 478 19.0 2.74 (1.76,4.32) 304 19.4 2.60 (1.26,5.59) 
Tobacco exposure*         
None 234 14.1 1  230 13.5 1  
Passive (secondhand) 
smoke 
312 22.8 1.92 (0.965,3.77) 312 22.8 1.92 (0.823,4.55) 
Active smoker 23 30.4 3.75 (1.23,10.8) 23 30.4 3.57 (0.978,13.0)§ 
Any sore throat reported *         
No 651 17.8 1      
Yes 208 25.5 1.66 (1.09,2.53)     
Any runny nose reported *         
No 184 20.7 1      
Yes 675 19.4 1.57 (0.995,2.51)     
Use gas as primary cooking 
fuel* 
        
No 832 20.0 1      
Yes 25 12.0 0.311 (0.0664,1.03)     
Completion of primary school 
(amongst over 17 years)* 
        
No 269 18.2 1      
Yes 99 11.1 0.381 (0.170,0.793)     
Household member 
completed secondary school* 
        
No 444 22.3 1      
Yes 415 16.9 0.670 (0.455,0.983)     
More than 2 participants per 
room* 
        
No 484 14.5 1      
Yes 
 
 
 
375 26.4 1.44 (0.996,2.10)     
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Factor 
Single risk factor analysis Multi-variable model 
Total 
Positive 
(%) OR 95% CI Total 
Positive 
(%) OR 95% CI 
Attending primary school 
(ages 5 to 17) 
        
No 52 25 1      
Yes 254 23.2 0.721 (0.325,1.65)     
Regular social meetings         
None 202 20.3 1      
1-2 per week 68 16.2 0.916 (0.404,1.96)     
3-4 per week 48 8.3 0.531 (0.141,1.61)     
5-7 per week 52 5.8 0.356 (0.0793,1.14)     
Index carrier in household         
No 259 12.0 1      
Yes 600 23.0 1.32 (0.826,2.16)     
Use wood as primary cooking 
fuel 
        
No 31 12.9 1      
Yes 828 19.9 1.02 (0.340,3.83)     
Indoor kitchen         
No 660 16.4 1      
Yes 199 30.7 1.28 (0.838,1.94)     
 365 
NB Total number of individuals may not sum to 861 in every case because of missing values. 366 
* p-value less than 0.1 in single risk factor analysis. 367 
§p-value less than 0.05.  368 
 369 
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Table 2. Risk factors for visit-by-visit N. meningitidis acquisition: single risk factor analysis and multi-370 
variable model. Adjustment was made a priori in both single and multi-variable analysis for age, 371 
country, and sex. 372 
Factor 
Single risk factor analysis (plus a priori) Multi-variable model 
Total 
Positive 
(%) OR 95% CI Total 
Positive 
(%) OR 95% CI 
Age         
30 plus     1504 1.8 1  
Under 5     1539 3.4 1.99 (1.22,3.32) 
5-14     2129 4.2 2.76 (1.75,4.48) 
15-29     1239 3 1.83 (1.08,3.15) 
Country         
Chad     990 0.6 1  
Ethiopia     564 4.6 7.54 (2.59,24.5) 
Ghana     828 3.5 5.7 (1.96,18.6) 
Mali     1574 0.9 1.51 (0.483,5.13) 
Niger     2281 5.2 11.5 (4.53,34.5) 
Senegal     174 7.5 14.2 (3.6,60.7) 
Sex         
Female     3405 2.9 1  
Male     3006 3.6 1.23 (0.907,1.68) 
Antibiotic taken*         
No 6592 3.5 1  6150 3.3 1  
Yes 261 0.8 0.197 (0.0323,0.623) 261 0.8 0.169 (0.0271,0.564) 
Interaction term*         
No sore throat, rainy 2643 3.3 1  2643 3.3 1  
No sore throat, dry 3481 2.8 0.88 (0.651,1.19) 3481 2.8 0.844 (0.617,1.16) 
Sore throat, rainy  123 2.4 0.906 (0.218,2.52) 123 2.4 0.82 (0.192,2.39) 
Sore throat, dry  164 11 3.72 (2.09,6.34) 164 11 3.67 (1.95,6.65) 
Sore throat*         
No 6566 3.3 1      
Yes 287 7.3 2.64 (1.58,4.19)     
Season         
Rainy: June to December 1944 3.1 1      
Dry: January to May 4467 3.3 1.07 (0.78,1.47)     
Meningitis vaccination         
No 5743 3.7 1      
Yes 1110 2 1.54 (0.899,2.55)     
Attendance at social event         
No 3319 4.4 1      
Yes 3534 2.5 0.851 (0.63,1.14)     
Travel greater than one 
hour 
        
No 6055 3.6 1      
Yes 798 2 0.955 (0.538,1.58)     
Cough         
No 5163 3.6 1      
Yes 1690 3 0.955 (0.682,1.31)     
Runny nose         
No 4634 3.8 1      
Yes 2219 2.6 0.961 (0.689,1.32)     
* p-value less than 0.1 in single risk factor analysis. 373 
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Table S1. Case definition for study-long acquisition. 375 
Classification Carriage at visits 0 or 1 Carriage at visits 2-9 
More than 3 
missed visits 
Number of 
individuals 
Not acquisition No No No 692 
Acquisition No Yes No 169 
Excluded No No Yes 231 
Excluded No Yes Yes 18 
Excluded Yes No No 42 
Excluded Yes No Yes 18 
Excluded Yes Yes No 159 
Excluded Yes Yes Yes 22 
 376 
Table S2. Case definition for visit-by-visit acquisition. 377 
Classification 
Carriage at 
previous visit 
Carriage at 
current visit 
Strain previously 
observed 
Number of 
visit pairs 
Not acquisition No No Not applicable 6768 
Acquisition No Yes No 226 
Acquisition Yes Yes No 47 
Excluded No Yes Yes 183 
Excluded Yes Yes Yes 366 
Excluded No No data Not applicable 1180 
Excluded Yes No Not applicable 516 
Excluded Yes No data Not applicable 128 
Excluded No data No Not applicable 1677 
Excluded No data Yes Not applicable 304 
Excluded No data No data Not applicable 2115 
 378 
Table S3. Odds of sore throat adjusting for age, country, sex and season. 379 
Factor Total Percent reporting sore throat OR 95% CI 
Age     
30 plus 2024 6.6 1  
Under 5 1914 2.4 0.372 (0.261,0.522) 
5-14 2806 2.6 0.399 (0.295,0.534) 
15-29 1752 7.4 1.13 (0.873,1.45) 
Country     
Chad 1038 5.8 1  
Ethiopia 940 7.1 1.27 (0.883,1.83) 
Ghana 1135 8.6 1.41 (1.01,1.98) 
Mali 1854 1.1 0.174 (0.101,0.287) 
Niger 3179 4.3 0.728 (0.532,1.01) 
Senegal 350 0   
Sex     
Female 4424 4.3 1  
Male 4072 4.6 1.14 (0.92,1.4) 
Season     
Rainy: June to December 3617 4.4 1  
Dry: January to May 4879 4.5 1.27 (1.02,1.57) 
 380 
  381 
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Table S4. Likelihood ratio test comparing visit-by-visit model with and without term of interaction 382 
between season and sore throat. 383 
 Chi-square 
Model Degrees of 
freedom 
AIC BIC Log-
likelihood 
Deviance Statistic Degrees of 
freedom 
p-value 
Acquisition ~ Age + Country + 
Sex + Sore throat + Antibiotic 
14 1660 1754 -815.82 1631.6    
Acquisition ~ Age + Country + 
Sex + Sore throat + Antibiotic 
+ Season 
15 1662 1763 -815.77 1631.5 0.099 1 0.75 
Acquisition ~ Age + Country + 
Sex + Sore throat + Antibiotic 
+ Season + Season and sore 
throat interaction 
16 1656 1764 -811.97 1623.9 7.6 1 0.006 
 384 
 385 
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